You are here: Industry Insights > Market News > Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis

expresspharmaOctober 22, 2020

Tag: cipla , Nintib , idiopathic pulmonary fibrosis , IPF

Favorites

Cipla has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib.

This launch marks a decade of Cipla’s foray into IPF treatment medicines, a rare lung disease that impacts ten in one lakh people.

Cipla’s Nintib is priced at Rs 69 (100 mg) and Rs. 85 (150 mg) per capsule.

Cipla introduced Pirfenex, generic Pirfenidone in 2010, the first-ever approved drug for IPF in India. Cipla reduced the cost of its IPF therapy by 40 per cent in 2013 to provide patient-access to this critical treatment.

Previous:COVID-19 vaccine delivery: Prepping for challenge extraordinaire

Next:Dr Reddy’s relaunch OTC Famotidine Tablets USP, 10 mg and 20 mg, in US

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Cipla launches Nintib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>